Published in

Wiley, Journal of Labelled Compounds and Radiopharmaceuticals, 13(50), p. 1176-1184, 2007

DOI: 10.1002/jlcr.1415

Links

Tools

Export citation

Search in Google Scholar

A pyrazolylamine-phosphonate monoester chelator for thefac-[M(CO)3]+ core (M = Re,99mTc): synthesis, coordination properties and biological assessment

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Aiming to develop new strategies for the labeling of hydroxyl-containing biomolecules with the organometallic core fac-[99mTc(CO)3]+, we have prepared a new model bifunctional chelator, L4 (ethyl hydrogen (2-{[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]amino}ethyl)phosphonate), combining a pyrazolyl-amine chelating group and a monophosphonate ethyl ester function (–P(O)OHOEt). The phosphonate group allows metal stabilization, and, simultaneously, can be considered as a potential attachment site for a biomolecule. Reaction of L4 with the precursor [99mTc(H2O)3(CO)3]+ gave the model radiocomplex [99mTc(CO)3(k3-L4)] (6a). This radiocomplex was identified by comparing its chromatographic profile with that of the corresponding Re analog (6) under the same conditions, also prepared and fully characterized by the usual analytical techniques. Radiocomplex 6a is moderately lipophilic (log Po/w = 1.07), presenting high stability in vitro without any measurable decomposition or ligand exchange, even in the presence of strong competing chelators such as histidine and cysteine (37°C, 24 h). Biodistribution studies of the complex in CD-1 mice indicated a rapid blood clearance, and a rapid clearance from main organs, occurring primarily through the hepatobiliary pathway. Complex 6a presents also a high robustness in vivo, demonstrated by its resistance to metabolic degradation in blood, and intact excretion into the urine, after RP-HPLC analysis of blood and urine samples. Copyright © 2007 John Wiley & Sons, Ltd.